Pharmacoeconomic evaluation of the effects of atorvastatin on early recurrent Ischemic events in acute coronary syndromes

被引：18

作者：

Schwartz, GG

Ganz, P

Waters, D

Arikian, S

机构：

[1] Vet Adm Med Ctr, Cardiol Sect 111B, Denver, CO 80220 USA

[2] Univ Colorado, Hlth Sci Ctr, Denver, CO USA

[3] Brigham & Womens Hosp, Boston, MA 02115 USA

[4] Harvard Univ, Sch Med, Boston, MA USA

[5] San Francisco Gen Hosp, San Francisco, CA 94110 USA

[6] Univ Calif San Francisco, San Francisco, CA 94143 USA

[7] Columbia Univ, Joseph L Mailman Sch Publ Hlth, New York, NY USA

[8] Analyt Grp Ltd, New York, NY USA

来源：

AMERICAN JOURNAL OF CARDIOLOGY | 2003年 / 92卷 / 09期

关键词：

D O I：

10.1016/j.amjcard.2003.06.009

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

An economic analysis was conducted using clinical outcomes in the MIRACL trial that evaluated high-dose atorvastatin versus placebo for 16 weeks after acute coronary syndrome. The direct cost of atorvastatin was largely offset by the associated decrease in cardiovascular events. The net incremental cost of atorvastatin treatment was $157/patient with a cost-effectiveness ratio of $4,086/event avoided. (C) 2003 by Excerpta Medica, Inc.

引用

页码：1109 / 1112

页数：4

共 20 条

[1]

*AG HEALTHC RES QU, 2002, OV HCUP NAT INP SAMP

[2]

*AM HEART ASS, 1995, METR LIF INS CO STAT

[3] A pharmacoeconomic evaluation of the Myocardial Ischaemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study in the United Kingdom [J].